Page 80 - Memoria FEHH - SEHH 2017

GRUPO ESPAÑOL DE SÍNDROMES MIELODISPLÁSICOS (GESMD)
Pósteres en congresos internacionales
MEMORIA ANUAL 2017 SOCIEDAD ESPAÑOLA
DE HEMATOLOGÍA Y HEMOTERAPIA
FUNDACIÓN ESPAÑOLA
DE HEMATOLOGÍA Y HEMOTERAPIA
• Acha P, Martin R, Palomo L, Ganster C, Dierks S, Mallo M, Ademà V, Fuster-Tormo F, Gómez-Marzo P, De Haro N, Jiménez-García F, Solanes N, Zamora L, Xicoy B, Kominowski A, Stromburg M, Brockmann A, Trümper L, Solé F, Ha- ase D. Targeted Deep Sequencing of peripheral CD34+ cells can reproduce bone marrow molecular profile in MDS patients. Ponencia. 14th International Symposium on Myelodysplastic Syndromes. 3-6 de mayo de 2017.
• Hurtado AM, Luengo-Gil G, Chen-Liang TH, Palomo L, Lumbreras E, Caparrós E, Przychodzen B, Amigo ML, Díez- Campelo M, Zamora L, Ortuño F, Vicente V, Maciejewski J, Del Cañizo C, Solé F, Ferrer-Marin F, Jerez A. DNA Repair Genes transcriptome in Chronic Myelomonocytic Leukemia. Ponencia. 14th International Symposium on Myelo- dysplastic Syndromes. 3-6 de mayo de 2017.
• Ganster C, Schaab R, Shirneshan K, Dierks S, Martin R, Cisneros A, Solé F, Germing U, Palomo L, Mies A, Braulke F, Hildebrandt B, Kaivers J, Platzbecker U, Kroeger N, Doehner K, Glass B, Nickelsen M, Schanz J, Bacher U, Haase D. Significance of molecular and cytogenetic TP53 status in MDS with complex karyotypes. Ponencia. 14th Inter- national Symposium on Myelodysplastic Syndromes. 3-6 de mayo de 2017.
• Palomo L, Malinverni R, Cabezón M, Xicoy B, Arnan M, Coll R, Pomares H, Grau J, Navarro T, Feliu E, Solé F, Busch- beck M, Zamora L. DNA methylation profiling in patients with CMML differs between normal and altered karyo- type. Póster. 14th International Symposium on Myelodysplastic Syndromes. 3-6 de mayo de 2017.
• Acha P, Xandri M, Fuster-Tormo F, Palomo L, Xicoy B, Cabezón M, Marcé S, Solé F, Zamora L. Usefulness of a Se- quencing Panel in Myeloproliferative Neoplasms Lacking Mutations in Driver Genes. Póster. Congreso America- no de Hematología 2017.
• Senent L, Lorenzo I, Vicente A, Alonso E, Sanzo C, Ramos F, Arenillas L, Orero MT, Navarro B, Ardanaz T, Marco V, Díez Campelo M, Jérez A, Montoro J, Arrizabalaga B, Bonanad S, Lluch R, De Paz R, Font P, Gomis F. Sanz G. Prognostic implication of the percentage of erythroid cells in bone marrow at diagnosis in patients with myelodysplastic syndrome. 14th International Symposium on Myelodysplastic Syndromes. 3-6 de mayo de 2017.
• Osorio Zuluaga J, Senent Peris ML, Guinot Segarra M, Saus Carreres A, Gomis Bernal F, Mayordomo E, Martínez i Cozar V, Vicente A, Sempere A, Lapiedra RA, Cervera J, Such E, Cordón L, Ibáñez MA, Barragán E, Sanz MA, Sanz GF. Bicytopenia workup on a bleeding patient. 14th International Symposium on Myelodysplastic Syndromes. 3-6 de mayo de 2017.
• Caballero Berrocal J. P318 in patients undegoing hematopoietic stem cell transplantation for mds development of chronic GVHD could ameliorate the adverse impact of specific somatic mutations. 14th International Sympo- sium on Myelodysplastic Syndromes. Mayo de 2017. Valencia, España.
• Redondo A. What is the outcome of patients in the intermediate IPSS-R score group? Spanish approach for better stratification with classical tools. Póster. 14th Internationa Symposium on Myelodisplastic Syndrome. Valen- cia, 3-6 de mayo de 2017.
• Cabrero M, Hernández-Sánchez JM, Caballero JC, Chillón C, Martín-Izquierdo M, Abáigar M, Redondo A, López- Cadenas F, Pérez López E, López-Corral L, Benito R, Robledo C, Del Rey M, González M, Del Cañizo C, Caballero D, Hernández-Rivas JM, Díez Campelo M. Evaluation of mutations at relapse in myelodysplastic syndrome patients receiving allogeneic stem cell transplantation. Póster. 22nd Congress of the European Hematology Association (EHA). Junio de 2017, Madrid, España.
80